The Therapeutic Goods Administration (TGA) is aware that, in Europe, atrioventricular blocks (including complete atrioventricular block) have been reported in patients receiving high doses of continuous intravenous infusion (100 micrograms/hour) of octreotide and in patients receiving bolus octreotide intravenously (50 micrograms bolus followed by 50 micrograms/hour continuous infusion). In Australia, the approved indications for octreotide do not involve intravenous administration.
Octreotide is an octapeptide that mimics natural somatostatin pharmacologically. It is a more potent inhibitor of growth hormone, glucagon and insulin than somatostatin.
It is marketed in Australia under the trade name Sandostatin and Sandostatin LAR (2.0 mL diluent), as well as various generic brands.
Octreotide is approved in Australia for the following indications:
For symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. Octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system:
carcinoid tumours with features of the carcinoid syndrome
For reduction of the incidence of complications following pancreatic surgery.
Additionally, Sandostatin LAR is also indicated for treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
The TGA has evaluated the risk of atrioventricular blocks associated with octreotide treatment in the Australian context. In Australia, the route of administration approved for octreotide products is only subcutaneous injection for the registered indications, while Sandostatin LAR may only be administered by deep intragluteal injection.
In Europe, octreotide (but not Sandostatin LAR) is approved for use in bleeding gastro-oesophageal varices with a continuous intravenous infusion as the route of administration. The European Union Summary of Product Characteristics (SmPC) for octreotide has been updated to advise that the maximum dose of 50 micrograms/hour should not be exceeded and that patients receiving high doses of intravenous octreotide should be kept under appropriate cardiac monitoring.
In Australia, some clinical guidelines, discuss the off-label use of octreotide in bleeding oesophageal varices with a dose of 50 micrograms by intravenous injection, followed by 50 micrograms/hour by continuous intravenous infusion for up to 5 days.
With this in mind, the TGA is advising health professionals of the identified risk of atrioventricular blocks in patients receiving off-label high doses of continuous infusion (100 micrograms/hour) of octreotide and in patients receiving bolus octreotide intravenously (50 micrograms bolus followed by 50 micrograms/hour continuous infusion).
The severity of atrioventricular block varies, with complete heart block resulting in cardiac arrest. Treatment may include pacemaker insertion.
The TGA has not seen an increase of adverse events of atrioventricular block associated with octreotide.
What to report? You don't need to be certain, just suspicious!
The TGA encourages the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies.
We particularly request reports of:
all suspected reactions to new medicines (look for the Black Triangle in PI and CMI documents - this symbol identifies medicines that are new or being used differently)
all suspected medicines interactions
suspected reactions causing death, admission to hospital or prolongation of hospitalisation, increased investigations or treatment, or birth defects.
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to email@example.com.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.